Alta Partners
Life sciences venture capital firm with a strong track record of building successful biotechnology companies. Known for hands-on company building and deep scientific expertise in therapeutics and healthcare.
Website
https://www.altapartners.comLocation
San Francisco, USA
Founded
1996
AUM
$1B+
Investment Range
$5M - $30M
Focus
biotech-focused
Fund Stages
seed, series-a, series-b, series-c
Investment Thesis
Alta Partners focuses on life sciences companies with breakthrough therapeutic potential, providing early-stage capital and operational support to build enduring companies. They take an active role in company building, leveraging their extensive network and experience to help companies achieve clinical and commercial milestones.
Team
Managing Directors
- Dan Janney - Managing Director
- Pete Hudson, M.D. - Managing Director
- Bob More - Managing Director
Other Key Team Members
- Larry Randall - Chief Financial Officer
Focus Areas
- Therapeutics
- Oncology
- Immunology
- Rare Diseases
- Gene Therapy
- Cell Therapy
- Precision Medicine
Notable Exits
- Amira Pharmaceuticals - Acquired (2011, by Bristol-Myers Squibb for $325M)
- NeurogesX - IPO (2007, NASDAQ: NGSX)
- CoTherix - Acquired (2007, by Actelion for $418M)
- Pharmacyclics - Acquired (2015, by AbbVie for $21B)